PolarityBio to Present Phase 3 SkinTE Data at SAWC Fall 2026
SALT LAKE CITY — September 29, 2026 PolarityBio announced that results from its pivotal Phase 3 COVER DFUS II...
Diabetic Foot Ulcers
Advertisement
Lakewood-Amedex Starts Phase 2a Trial of Nu-3 for Foot Ulcers
San Diego, California, U.S., September 24, 2026 Lakewood-Amedex Biotherapeutics has announced that the first patient has been dosed in...
Flen Health and AGC Biologics Advance Enzyme Wound Therapy
Heidelberg, Germany, September 24, 2026 Flen Health has selected AGC Biologics as its contract development and manufacturing organization (CDMO)...
Lakewood-Amedex Advances Nu-3 Phase 2a Clinical Trial
Sarasota, Florida, September 18, 2026 Lakewood-Amedex Biotherapeutics Inc. has announced that it has received central and all clinical-site Institutional...
PolarityBio Gains FDA Priority Review for SkinTE in DFUs
SALT LAKE CITY, Utah — September 15, 2026 PolarityBio announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
Organogenesis Publishes Positive Affinity Trial Results for Venous Leg Ulcers
CANTON, Mass., July 27, 2026 Organogenesis Holdings Inc. announced the publication of peer-reviewed clinical trial results demonstrating the effectiveness...
Merakris Therapeutics Wins NIH Funding for MTX-001
RESEARCH TRIANGLE PARK, N.C., July 21, 2026 Merakris Therapeutics announced that it has received a Direct-to-Phase II Small Business...
Lakewood-Amedex Advances Nu-3 Gel Toward Phase 2a Trial
SARASOTA, Fla., July 15, 2026 Lakewood-Amedex Biotherapeutics Inc. has announced encouraging preclinical safety results supporting dose selection for the...
FibroBiologics Doses First Patients in Phase 1/2 Trial of CYWC628 for Diabetic Foot Ulcers
HOUSTON, June 16, 2026 FibroBiologics announced that the first patients have been dosed in its ongoing Phase 1/2 clinical...
Advertisement
